BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Core Insights - BriaCell Therapeutics Corp. announced positive survival data from its Phase 2 study of Bria-IMT combined with checkpoint inhibitors, showing better outcomes than current ADC drugs for HR+ metastatic breast cancer patients [1][2][4] Clinical Study Results - In the Phase 2 study, 25 out of 37 patients with HR+ breast cancer treated with Bria-IMT had a median overall survival of 17.3 months, surpassing the 14.4 months seen with TRODELVY® [2][4] - For triple-negative breast cancer (TNBC) patients, the survival data with Bria-IMT was comparable to TRODELVY® but significantly higher (70%) than traditional chemotherapy [2][4] - The study included 54 heavily pre-treated metastatic breast cancer patients, with a median of 6 prior treatments [5] Company Statements - Dr. William V. Williams, President and CEO of BriaCell, expressed confidence in the survival benefit data and the tolerability of Bria-IMT, looking forward to further confirmation in the ongoing Phase 3 study [3][4] - Dr. Giuseppe Del Priore, Chief Medical Officer, highlighted the potential of Bria-IMT + CPI to meet the unmet medical needs of HR+ and TNBC patients, who have limited treatment options [3][4] Additional Information - No discontinuations related to Bria-IMT have been reported to date, indicating a favorable safety profile [4][5] - The ongoing pivotal Phase 3 study is listed on ClinicalTrials.gov as NCT06072612 [5]